Advances for purchase of
intangible assets (1,918,791) 836,404
Net Cash from Investing Activities (2,343,864) 872,497
Cash Flows from Financing Activities:
Proceeds from sale of common stock
and warrants -- 3,797,183
Payments of short term notes payable (376,271) --
Related party payables/receivables -- (138,860)
Net Cash from Financing Activities (376,271) 3,658,323
Effect of Exchange Rate Changes on Cash 50,539 5,247
Net Change in Cash (1,148,318) 2,294,277
Cash and Cash Equivalents at Beginning
of Period 1,830,335 656,441
Cash and Cash Equivalents at End of
Period $682,017 $2,950,718
Supplemental Cash Flow Disclosure:
Cash paid for interest $83,515 $56,899
Cash paid for income taxes -- --
'/>"/>SOURCE China Pharma Holdings, Inc. Copyright©2008 PR Newswire. All rights reserved | |
Page: 1 2 3 4 5 6 7 8 9 Related biology technology :1.
China Biologic Products Announces SFDA Approval for the Production of Cryoprecipitate and for the Clinical Trial of Human Prothrombin Complex2.
DuPont Partnering with China to Increase Farm Productivity3.
China Yingxia International, Inc. Acquires Grocery Chain and Online Distribution Network4.
China Sky One Medical, Inc. Acquires Heilongjiang Haina Pharmaceutical Inc.5.
Syngenta To Build Major Global Biotech Research Center in Beijing, China6.
American Oriental Bioengineering and China Aoxing Pharmaceutical Enter Into Strategic Alliance7.
China YCT International Group, Inc. Announces Entrusted Management Agreement With Its Primary Supplier8.
CTDC Attends the Inauguration Ceremony of Thin Film A-Si Manufacturing Line in Changzhou, China9.
China Bio Energy Reports Fiscal 2007 Financial Results10.
Transgenomic Opens Pharmacogenomics Laboratory in China11.
China Pharma Holdings, Inc. Announces Record 2007 Year End Results